BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Twu O, Mednik S, Scumpia P, Doaty S, Worswick S. Use of Becaplermin for nondiabetic ulcers: pyoderma gangrenosum and calciphylaxis. Dermatol Ther 2016;29:104-8. [PMID: 26556220 DOI: 10.1111/dth.12318] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Vallini V, Andreini R, Bonadio A. Pyoderma Gangrenosum: A Current Problem as Much as an Unknown One. The International Journal of Lower Extremity Wounds 2017;16:191-201. [DOI: 10.1177/1534734617710980] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hall C, Hardin C, Corkins CJ, Jiwani AZ, Fletcher J, Carlsson A, Chan R. Pathophysiologic Mechanisms and Current Treatments for Cutaneous Sequelae of Burn Wounds. Compr Physiol 2017;8:371-405. [PMID: 29357133 DOI: 10.1002/cphy.c170016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
3 Nigwekar SU. Calciphylaxis. Curr Opin Nephrol Hypertens 2017;26:276-81. [PMID: 28375870 DOI: 10.1097/MNH.0000000000000328] [Cited by in Crossref: 32] [Cited by in F6Publishing: 9] [Article Influence: 10.7] [Reference Citation Analysis]
4 Plumptre I, Knabel D, Tomecki K. Pyoderma Gangrenosum: A Review for the Gastroenterologist. Inflamm Bowel Dis 2018;24:2510-7. [PMID: 29788368 DOI: 10.1093/ibd/izy174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
5 Seethapathy H, Nigwekar SU. Revisiting therapeutic options for calciphylaxis: . Current Opinion in Nephrology and Hypertension 2019;28:448-54. [DOI: 10.1097/mnh.0000000000000520] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]